{
    "root": "2f392531-5fdf-1863-e063-6394a90af7f3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "SODIUM PHENYLACETATE AND SODIUM BENZOATE",
    "value": "20250228",
    "ingredients": [
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "SODIUM PHENYLACETATE",
            "code": "48N6U1781G"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU"
        }
    ],
    "indications": "sodium phenylacetate sodium benzoate injection indicated adjunctive therapy pediatric adult patients treatment acute hyperammonemia associated encephalopathy patients deficiencies enzymes urea cycle . acute hyperammonemic episodes , arginine supplementation , caloric supplementation , dietary protein restriction , hemodialysis , ammonia lowering therapies considered [ ( 5 ) ] .",
    "contraindications": "sodium phenylacetate sodium benzoate injection must diluted sterile 10 % dextrose injection ( d10w ) . must central venous catheter . peripheral line may cause burns . ( 2 ) sodium phenylacetate sodium benzoate injection administered intravenously loading dose infusion administered 90 120 minutes , followed equivalent maintenance dose infusion administered 24 hours . ( 2 ) full prescribing information complete dosing recommendations .",
    "warningsAndPrecautions": "sodium phenylacetate sodium benzoate injection 10 % per 10 % supplied sterile , non-pyrogenic , single glass vial . ndc 68682-001-50 single vial containing 50 ml sodium phenylacetate sodium benzoate injection 10 % per 10 % . storage : store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) .",
    "adverseReactions": "none .",
    "indications_original": "Sodium Phenylacetate and Sodium Benzoate Injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [see\n \n  \n                        Warnings and Precautions (5)\n                     ].",
    "contraindications_original": "Sodium Phenylacetate and Sodium Benzoate Injection must be diluted with sterile 10% Dextrose Injection (D10W) before administration. Administration must be through a central venous catheter. Administration through a peripheral line may cause burns. ( 2 ) Sodium Phenylacetate and Sodium Benzoate Injection is administered intravenously as a loading dose infusion administered over 90 to 120 minutes, followed by an equivalent maintenance dose infusion administered over 24 hours. ( 2 ) See Full Prescribing Information for complete dosing recommendations.",
    "warningsAndPrecautions_original": "Sodium Phenylacetate and Sodium Benzoate Injection 10% per 10% is supplied in a sterile, non-pyrogenic, single use glass vial.\n                  NDC 68682-001-50 single use vial containing 50 mL of Sodium Phenylacetate and Sodium Benzoate Injection 10% per 10%.\n                  \n                     Storage: Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F).",
    "adverseReactions_original": "None."
}